 SEATTLE--BUSINESS WIRE--Silverback Therapeutics, Inc. Nasdaq: SBTX Silverback, a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical results from a Phase 11b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced 